This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Genetics  • Genetic Disorders  • Neurology  • Neuro-ophthalmology  • Ophthalmological Disorders, Other  • Alert me on articles by topic

Neroli Porter, MBBS, FRANZCO; Susan M. Downes, MD, FRCOphth; Carl Fratter, MPhil, DipRCPath; Philip Anslow, MA, MBBChir, FRCR; Andrea H. Németh, MBBS, MRCP, DPhil (Oxon)

Arch Ophthalmol. 2007;125(2):273-274.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder usually characterized by progressive early-onset ataxia. The most common ophthalmic manifestation of FRDA is optic neuropathy, which is usually late in onset, is slowly progressive, and rarely causes severe visual loss.¹ The genetic basis of FRDA in most patients is the homozygous expansion of a GAA trinucleotide repeat within the first intron of the FRDA gene, which encodes the mitochondrial protein frataxin. Mutations in frataxin cause progressive iron accumulation in mitochondria. Four percent of patients are compound heterozygotes for the GAA expansion on one allele and a point mutation on the other.² We describe a patient with FRDA who was a compound heterozygote for the GAA expansion and a Gly130Val missense mutation, developed rapid-onset catastrophic visual . . . [Full Text of this Article]

Report of a Case


Comment

AUTHOR INFORMATION